Sector News

AstraZeneca continues China push with logistics center

June 7, 2016
Life sciences

As some Big Pharma players have struggled in China recently, AstraZeneca has managed to keep up its double-digit sales growth there through the first quarter.

Now, to meet strong demand, the U.K. pharma has opened a $40 million logistics center to store and ship medicines from its global outposts.

The opening of AstraZeneca’s supply chain facility, located in the Wuxi National Hi-tech District, marks the company’s move to regionalize production, logistics and sales, Chinadaily reports. AZ began construction on the project in 2014 and will turn over operations to logistics specialist DHL.

The pharma is not new to the area. It has had its Wuxi manufacturing outfit since 2001, with its total investment at the site tallying $555 million. That’s set to expand, according to Chinadaily, as AZ has signed a memorandum of understanding with the district stating that it intends to invest more to boost production.

For AZ, the opening follows a strong Q1 in China, during which it posted sales gains of 11%. Luke Miels, EVP for global product and portfolio strategy, said at the time that the company’s product mix was “extremely competitive,” with Pulmicort Respules serving as the top multinational pharma drug in the country. Nexium and Crestor joined it in the top 15.

While China was a Q1 source of strength for AZ, some of the company’s peers haven’t been as lucky there. The country’s recent moves to curb healthcare spending have taken a toll at Bayer and GlaxoSmithKline ($GSK), with GSK’s China sales tumbling 28% in the first quarter.

In another move to build up its presence in the area, AstraZeneca inked a deal in December to buy a $100 million biologics plant from WuXi PharmaTech as that company invests in new capacity. AZ is also working to build out an existing small-molecule drug plant and to build a local R&D hub for small molecules and biologics.

By Eric Sagonowsky

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend